222 related articles for article (PubMed ID: 24657693)
1. Therapeutic targets in heart failure: refocusing on the myocardial interstitium.
Schelbert EB; Fonarow GC; Bonow RO; Butler J; Gheorghiade M
J Am Coll Cardiol; 2014 Jun; 63(21):2188-98. PubMed ID: 24657693
[TBL] [Abstract][Full Text] [Related]
2. A look between the cardiomyocytes: the extracellular matrix in heart failure.
Miner EC; Miller WL
Mayo Clin Proc; 2006 Jan; 81(1):71-6. PubMed ID: 16438481
[TBL] [Abstract][Full Text] [Related]
3. Employing Extracellular Volume Cardiovascular Magnetic Resonance Measures of Myocardial Fibrosis to Foster Novel Therapeutics.
Schelbert EB; Sabbah HN; Butler J; Gheorghiade M
Circ Cardiovasc Imaging; 2017 Jun; 10(6):. PubMed ID: 28512159
[TBL] [Abstract][Full Text] [Related]
4. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure.
Brown RD; Ambler SK; Mitchell MD; Long CS
Annu Rev Pharmacol Toxicol; 2005; 45():657-87. PubMed ID: 15822192
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart.
Creemers EE; Pinto YM
Cardiovasc Res; 2011 Feb; 89(2):265-72. PubMed ID: 20880837
[TBL] [Abstract][Full Text] [Related]
6. CCN2 plays a key role in extracellular matrix gene expression in severe hypertrophic cardiomyopathy and heart failure.
Tsoutsman T; Wang X; Garchow K; Riser B; Twigg S; Semsarian C
J Mol Cell Cardiol; 2013 Sep; 62():164-78. PubMed ID: 23756156
[TBL] [Abstract][Full Text] [Related]
7. Implications of myocardial matrix remodeling by adipokines in obesity-related heart failure.
Schram K; Sweeney G
Trends Cardiovasc Med; 2008 Aug; 18(6):199-205. PubMed ID: 19185809
[TBL] [Abstract][Full Text] [Related]
8. Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-β.
Edgley AJ; Krum H; Kelly DJ
Cardiovasc Ther; 2012 Feb; 30(1):e30-40. PubMed ID: 21883991
[TBL] [Abstract][Full Text] [Related]
9. Increased production of CXCL16 in experimental and clinical heart failure: a possible role in extracellular matrix remodeling.
Dahl CP; Husberg C; Gullestad L; Waehre A; Damås JK; Vinge LE; Finsen AV; Ueland T; Florholmen G; Aakhus S; Halvorsen B; Aukrust P; Oie E; Yndestad A; Christensen G
Circ Heart Fail; 2009 Nov; 2(6):624-32. PubMed ID: 19919988
[TBL] [Abstract][Full Text] [Related]
10. Osteopontin: a potential biomarker for heart failure and reverse remodeling after left ventricular assist device support.
Schipper ME; Scheenstra MR; van Kuik J; van Wichen DF; van der Weide P; Dullens HF; Lahpor J; de Jonge N; De Weger RA
J Heart Lung Transplant; 2011 Jul; 30(7):805-10. PubMed ID: 21531579
[TBL] [Abstract][Full Text] [Related]
11. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
Dieterich HA; Wendt C; Saborowski F
Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
[TBL] [Abstract][Full Text] [Related]
12. Differential regulation of extracellular matrix constituents in myocardial remodeling with and without heart failure following pressure overload.
Skrbic B; Bjørnstad JL; Marstein HS; Carlson CR; Sjaastad I; Nygård S; Bjørnstad S; Christensen G; Tønnessen T
Matrix Biol; 2013 Mar; 32(2):133-42. PubMed ID: 23220517
[TBL] [Abstract][Full Text] [Related]
13. The cellular and physiologic effects of beta blockers in heart failure.
Sabbah HN
Clin Cardiol; 1999 Oct; 22 Suppl 5():V16-20. PubMed ID: 10526699
[TBL] [Abstract][Full Text] [Related]
14. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients.
Lin YH; Lin LY; Wu YW; Chien KL; Lee CM; Hsu RB; Chao CL; Wang SS; Hsein YC; Liao LC; Ho YL; Chen MF
Clin Chim Acta; 2009 Nov; 409(1-2):96-9. PubMed ID: 19747906
[TBL] [Abstract][Full Text] [Related]
15. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.
Paulus WJ; Tschöpe C
J Am Coll Cardiol; 2013 Jul; 62(4):263-71. PubMed ID: 23684677
[TBL] [Abstract][Full Text] [Related]
16. SIRT3 as a potential therapeutic target for heart failure.
Chen J; Chen S; Zhang B; Liu J
Pharmacol Res; 2021 Mar; 165():105432. PubMed ID: 33508434
[TBL] [Abstract][Full Text] [Related]
17. Why Clinicians Should Care About the Cardiac Interstitium.
Schelbert EB; Butler J; Diez J
JACC Cardiovasc Imaging; 2019 Nov; 12(11 Pt 2):2305-2318. PubMed ID: 31422140
[TBL] [Abstract][Full Text] [Related]
18. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction.
Westermann D; Lindner D; Kasner M; Zietsch C; Savvatis K; Escher F; von Schlippenbach J; Skurk C; Steendijk P; Riad A; Poller W; Schultheiss HP; Tschöpe C
Circ Heart Fail; 2011 Jan; 4(1):44-52. PubMed ID: 21075869
[TBL] [Abstract][Full Text] [Related]
19. Induced adipocyte cell-sheet ameliorates cardiac dysfunction in a mouse myocardial infarction model: a novel drug delivery system for heart failure.
Imanishi Y; Miyagawa S; Maeda N; Fukushima S; Kitagawa-Sakakida S; Daimon T; Hirata A; Shimizu T; Okano T; Shimomura I; Sawa Y
Circulation; 2011 Sep; 124(11 Suppl):S10-7. PubMed ID: 21911798
[TBL] [Abstract][Full Text] [Related]
20. Integrating the myocardial matrix into heart failure recognition and management.
Spinale FG; Zile MR
Circ Res; 2013 Aug; 113(6):725-38. PubMed ID: 23989715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
